Teva Pharmaceutical Industries (NYSE:TEVA) Earns “Neutral” Rating from Credit Suisse Group

Credit Suisse Group reiterated their neutral rating on shares of Teva Pharmaceutical Industries (NYSE:TEVA) in a research report sent to investors on Wednesday morning, Briefing.com Automated Import reports.

Several other research firms also recently issued reports on TEVA. Wells Fargo & Co set a $17.00 price target on Teva Pharmaceutical Industries and gave the stock a hold rating in a research note on Tuesday, May 28th. BMO Capital Markets set a $66.00 price target on CyrusOne and gave the stock a buy rating in a research note on Friday, May 3rd. ValuEngine downgraded Wave Life Sciences from a strong-buy rating to a buy rating in a research note on Monday, March 25th. Mizuho set a $11.00 price target on Teva Pharmaceutical Industries and gave the stock a hold rating in a research note on Monday, June 17th. Finally, Maxim Group reiterated a hold rating on shares of Arlington Asset Investment in a research note on Thursday, May 2nd. Five equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of Hold and a consensus price target of $15.83.

TEVA opened at $9.25 on Wednesday. The company has a market cap of $9.12 billion, a P/E ratio of 3.30, a PEG ratio of 1.07 and a beta of 1.62. The business’s 50-day moving average is $9.13. Teva Pharmaceutical Industries has a 52-week low of $7.96 and a 52-week high of $25.96. The company has a debt-to-equity ratio of 1.66, a quick ratio of 0.62 and a current ratio of 0.96.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Thursday, May 2nd. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.02. The company had revenue of $4.30 billion during the quarter, compared to the consensus estimate of $4.38 billion. Teva Pharmaceutical Industries had a positive return on equity of 16.84% and a negative net margin of 18.66%. The firm’s revenue was down 15.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.94 EPS. On average, research analysts predict that Teva Pharmaceutical Industries will post 2.27 EPS for the current year.

In related news, VP Notaristefani Carlo De sold 16,070 shares of the stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $11.42, for a total transaction of $183,519.40. Following the completion of the sale, the vice president now owns 49,659 shares in the company, valued at approximately $567,105.78. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Sol J. Barer bought 111,000 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were acquired at an average price of $8.98 per share, with a total value of $996,780.00. Following the purchase, the director now owns 115,942 shares in the company, valued at $1,041,159.16. The disclosure for this purchase can be found here. 0.49% of the stock is owned by corporate insiders.

A number of institutional investors have recently bought and sold shares of the business. Cutler Capital Management LLC purchased a new position in shares of Teva Pharmaceutical Industries during the 4th quarter valued at approximately $2,539,000. Prudential Financial Inc. increased its holdings in Teva Pharmaceutical Industries by 105.5% in the 4th quarter. Prudential Financial Inc. now owns 218,134 shares of the company’s stock worth $3,364,000 after acquiring an additional 111,965 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Teva Pharmaceutical Industries by 3.5% in the 4th quarter. Bank of New York Mellon Corp now owns 1,975,038 shares of the company’s stock worth $30,454,000 after acquiring an additional 67,168 shares in the last quarter. Raymond James Financial Services Advisors Inc. increased its holdings in Teva Pharmaceutical Industries by 2.0% in the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 76,187 shares of the company’s stock worth $1,175,000 after acquiring an additional 1,497 shares in the last quarter. Finally, Northern Trust Corp increased its holdings in Teva Pharmaceutical Industries by 2.7% in the 4th quarter. Northern Trust Corp now owns 6,687,764 shares of the company’s stock worth $103,125,000 after acquiring an additional 175,173 shares in the last quarter. 65.08% of the stock is owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

See Also: Stock Symbols and CUSIP Explained

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.